A study featuring monoclonal antibody treatments (mAbs) Sotrovimab, Evusheld et al, and antiviral treatments Molnupiravir, Remdesivir and a Pfizer antiviral in development (not Paxlovid).
In vitro, the above-named all showed efficacy against the Omicron variant, while mAb combinations from Eli Lilly and Regeneron did not.
The mAb results are in line with earlier in vitro studies, but these give independent corroboration nejm.org/doi/full/10.1056/N...
Wow! Thanks for sharing this. It shows much better efficacy for Evusheld (a combo of tixagevimab–cilgavimab) than was asserted in this earlier report. I realize they're all in vitro studies, but I wonder why the outcomes are so different.
forbes.com/sites/williamhas...
Actually, now I need to ask if S309 is basically the same as sotrovimab. It's listed as a precursor. After skimming thru this link (and my eyes glazing over), I'm officially in the weeds on this question. fda.gov/media/150130/download I guess my question is whether the latest iteration of sotrovimab was used in this assay. Its availability here in the US is all but nonexistent, but it's certainly relevant to all of you in the UK.
Re Evusheld, good question, too good for me I'm afraid.
Re Sotrovimab precursor, no idea what they mean. VIR7831 has been unchanged for ages, phase 3 Comet-Ice trial started Aug 2020.
Maybe it's a nomenclature difference between the US and the EU?
On the US FDA page I linked above, it says, “On Page 42 of the summary EUA [emergency use authorization] review in the Summary of Data Reviewed for Nonclinical Virology Studies subsection, sotrovimab (S309) should instead be noted as sotrovimab (derived from S309). [my emphasis] This correction replaces the notation in all three instances in the May 26, 2021 summary EUA review.)"
But as you suggested, the EU refers to it as VIR-7831 ema.europa.eu/en/news/ema-i...
Go figure... 🤔
S309 being the antibody as isolated from serum of a recovered Covid patient. The essence of vir7831 forbes.com/sites/williamhas... Is that what the Tokyo researchers tested?
Clinical Trials of Monoclonal antibodies AZD7442 against SARS=CoV-2 (COVID19) - majority of sites in UK and USA
The failing effectiveness of COVID-19 monoclonal antibodies against BA.1, BA.4-5, BA.4.6, BA.2.75, BJ.1 and BQ.1.1
RISK OF DYING OF COVID DURING THIS OMICRON PHASE
The possible efficacy of BTK inhibitors lessening the effects of COVID-19
Important SARS-CoV-2 and Covid-19 information for Chronic Lymphocytic Leukaemia/CLL patients
